{"nctId":"NCT00404820","briefTitle":"Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis","startDateStruct":{"date":"2006-10"},"conditions":["Osteoporosis"],"count":604,"armGroups":[{"label":"Zoledronic acid 5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Zoledronic acid 5 mg solution","Drug: Calcium/Vitamin D"]},{"label":"Alendronate 70 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Alendronate 70 mg tablets","Drug: Calcium/Vitamin D"]}],"interventions":[{"name":"Zoledronic acid 5 mg solution","otherNames":[]},{"name":"Alendronate 70 mg tablets","otherNames":[]},{"name":"Calcium/Vitamin D","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n\\- Low bone mineral density (as indicated by a \"t-score\" of -2.0 or lower) postmenopausal women\n\nExclusion Criteria:\n\n\\- Previous use of oral and iv bisphosphonates, parathormone, strontium ranelate, sodium fluoride.\n\nOther protocol-defined inclusion/exclusion criteria applied to the study.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"55 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change of Cross-linked N-telopeptide of Type I Collagen (NTx) Level Assessed as Standardized Area Under the Curve From Screening to Month 12 in the Intent-to-Treat Population","description":"The level of bone activity as measured by NTx over the course of 12 months was assessed using the standardized area under the curve. Blood samples were collected after an overnight fast of at least 8 hours between 7:00 and 11:00 AM at Screening and Months 1.5, 3, 6, 9, and 12 months after baseline. Serum was analyzed at a central lab using commercially available ELISA kits. Standardized AUC was calculated by the AUC divided by the number of days the patient participated in the study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.282","spread":"0.195"},{"groupId":"OG001","value":"0.270","spread":"0.266"}]}]}]},{"type":"SECONDARY","title":"Change of Procollagen Type I Nitrogenous Propeptide (P1NP) Level Assessed as Standardized Area Under the Curve From Screening to Month 12","description":"The level of bone activity as measured by P1NP over the course of 12 months was assessed using the standardized area under the curve. Blood samples were collected after an overnight fast of at least 8 hours between 7:00 and 11:00 AM at Screening and Months 1.5, 3, 6, 9, and 12 months after baseline. Serum was analyzed at a central lab using commercially available ELISA kits. Standardized AUC was calculated by the AUC divided by the number of days the patient participated in the study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.2","spread":"23.0"},{"groupId":"OG001","value":"25.5","spread":"17.6"}]}]}]},{"type":"SECONDARY","title":"Change in the Qualeffo-41 Quality of Life (QoL) Questionnaire Score From Baseline to Month 12","description":"The Qualeffo-41 QoL questionnaire was completed by the patient at Baseline and at Month 12. The questionnaire includes 41 questions covering 7 domains (pain, physical function and activities of daily living, physical function and jobs around the house, physical function and mobility, leisure and social activities, general health perception, mental function). Scores on each question range from 1 to 3, 4, or 5. The total score summed over all questions ranges from 41-205 points; the lower the score the higher the quality of life. A negative change score indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"8.8"},{"groupId":"OG001","value":"-0.6","spread":"9.0"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With a Clinical Fracture From Baseline to Month 12","description":"A diagnosis of clinical fracture was based on physical examination findings, ie, swelling, tenderness, limited movement, pain.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Body Height From Baseline to Month 12","description":"Body height was measured at Baseline and at the end of the study (Month 12) and the change in height calculated.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.0"},{"groupId":"OG001","value":"0.0","spread":"1.2"}]}]}]},{"type":"SECONDARY","title":"Therapy Preference at End of Study (Month 12)","description":"Patients were administered a questionnaire at the end of the study in which they were asked which type of therapy, weekly oral or yearly iv, they preferred.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"330","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"93","spread":null}]}]}]},{"type":"PRIMARY","title":"Change of Cross-linked N-telopeptide of Type I Collagen (NTx) Level Assessed as Standardized Area Under the Curve From Screening to Month 12 in the Per Protocol Population","description":"The level of bone activity as measured by NTx over the course of 12 months was assessed using the standardized area under the curve. Blood samples were collected after an overnight fast of at least 8 hours between 7:00 and 11:00 AM at Screening and Months 1.5, 3, 6, 9, and 12 months after baseline. Serum was analyzed at a central lab using commercially available ELISA kits. Standardized AUC was calculated by the AUC divided by the number of days the patient participated in the study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.293","spread":"0.199"},{"groupId":"OG001","value":"0.294","spread":"0.175"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":43,"n":408},"commonTop":["Influenza like illness","Arthralgia","Back pain","Headache","Nasopharyngitis"]}}}